revealed a gene signature of tissue-resident memory CD8+ T cells rather than the CD8 alone could better predict the patient’s survival, suggesting these cells are potential regulatory targets of immunotherapy in breast cancer (121). This evidence concerns the gene CD8A and breast carcinoma.